abbvie glp-1 receptor agonist Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch Polyagonists Enable Increasingly Effective Treatment

Consider Other Prescription Weight Loss Drugs Long before Ozempic became a blockbuster, the FDA approved a variety of other medications to help people slim down

doi: 10.1007/s13300-025-01784-x [DOI] [PMC free article] [PubMed] [Google Scholar] 205.Packer M, Zile MR, Kramer CM, et al

This is highlighted by its notably highest values across various statistical parameters, including an IC at 4.17 (IC025 3.98), an ROR at 20.13 (95% CI 19.2121.09), and an EBGM at 18.04 (EBGM05 17.35)

Monitoring your progress and making the right call The decision to continue, reduce, or stop GLP-1 therapy should be driven by data, not arbitrary timelines or gut feelings

doi: 10.1111/dom.12651 68 HeinlaKVasarESedmanTVolkeV

Tissue inhibitors of metalloproteinases